Saturday 17 October 2026 Export REPL’s income statement to Excel — free account

Replimune Group, Inc.

In the quarter to June 2026, EPS grew 24.2%, free cash flow grew 5.04% and total debt rose 52.6%, each against the same quarter a year earlier.

10.86 0.89 −7.57%

Follow REPL

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.93

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	2	—	—	—	1	6	1	—	5	—	—

Insider Ownership 8.52%

Capital & Financial Ratios $m

Market Cap 1,110.00

Revenue —

Net Income (297.01)

Free Cash Flow (280.54)

Net Debt (89.53)

Current Ratio 5.23

Debt/Equity 1.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 9.96

Past 5Y EPS Growth —

This Y EPS Growth 14.60%

Next Y EPS Growth 33.89%

Next Y revenue growth —

Next 5Y EPS Growth 40.56%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 96.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	421	484	269	195
Receivables	5	4	2	—
Inventory	—	—	—	—
Other	—	—	—	—
	434	496	279	201

	2024	2025	2026	Q'26
Payables	3	12	7	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	40	62	58	38

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(19.73%)	(33.11%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(76)	—	—	—	—
’26	(77)	(81)	(66)	(56)	(280)
’25	(49)	(39)	(51)	(54)	(192)
’24	(49)	(44)	(47)	(46)	(185)
’23	(33)	(33)	(29)	(33)	(128)
’22	(18)	(23)	(18)	(23)	(82)
’21	(15)	(17)	(13)	(16)	(61)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(76)	—	—	—	—
’26	(80)	(83)	(66)	(56)	(285)
’25	(51)	(41)	(53)	(55)	(199)
’24	(49)	(45)	(49)	(48)	(191)
’23	(35)	(34)	(29)	(33)	(130)
’22	(19)	(23)	(19)	(24)	(85)
’21	(16)	(17)	(14)	(17)	(64)

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.72)	—	—	—	—
’26	(0.95)	(0.90)	(0.77)	(0.76)	(3.38)
’25	(0.78)	(0.68)	(0.79)	(0.82)	(3.07)
’24	(0.75)	(0.90)	(0.77)	(0.82)	(3.24)
’23	(0.78)	(0.79)	(0.69)	(0.74)	(2.99)
’22	(0.53)	(0.56)	(0.57)	(0.60)	(2.26)
’21	(0.44)	(0.46)	(0.44)	(0.41)	(1.75)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	9.61	8.88	8.58	24.85	13.05	5.89	4.92	2.68	1.50	Analyst estimates 2027–2029 Powerpack
	High	—	23.55	18.25	54.85	46.64	30.89	29.52	17.00	14.80	16.33
People
People	Employees	—	44	67	122	152	206	284	331	479	465
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(8)	(20)	(31)	(53)	(81)	(118)	(174)	(215)	(247)	(314)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(8)	(20)	(31)	(53)	(81)	(118)	(174)	(216)	(247)	(314)
	Depreciation	0	0	(2)	0	3	4	(3)	(10)	(5)	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(1.55)	(3.96)	(1.33)	(1.54)	(1.75)	(2.26)	(2.99)	(3.24)	(3.07)	(3.38)
	Cash flow	(1.42)	(3.22)	(1.09)	(1.77)	(1.33)	(1.57)	(2.20)	(2.79)	(2.39)	(3.02)
	Capex	(0.05)	(0.03)	(0.11)	(0.19)	(0.05)	(0.04)	(0.04)	(0.09)	(0.08)	(0.05)
	Free cash flow	(1.47)	(3.24)	(1.21)	(1.96)	(1.38)	(1.62)	(2.24)	(2.87)	(2.47)	(3.07)
	Book value	(2.32)	(5.64)	5.94	5.36	10.78	7.88	9.54	5.63	5.16	1.79
	Shares, m	5	5	23	34	46	52	58	67	81	93
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(7)	(16)	(25)	(61)	(61)	(82)	(128)	(185)	(192)	(280)
	Capex	0	0	(3)	(7)	(2)	(2)	(2)	(6)	(7)	(4)
	Free cash flow	(7)	(16)	(28)	(67)	(64)	(85)	(130)	(191)	(199)	(285)
Balance, $m
Balance, $m	Working capital	20	60	131	162	469	383	559	393	434	221
	Total debt	—	—	7	35	25	24	53	68	69	105
	Net debt	(21)	(62)	(128)	(134)	(452)	(371)	(531)	(352)	(415)	(164)
	Shareholders’ equity	(12)	(28)	138	184	499	411	555	375	416	166
Returns, %
Returns, %	ROA	(17.52)	(44.79)	(28.10)	(27.10)	(20.81)	(23.51)	(31.47)	(38.05)	(47.60)	(71.05)
	ROIC	0.00	0.00	(201.35)	(70.34)	(105.94)	(184.96)	(451.38)	(665.18)	(14,280.95)	(8,036.55)
	ROE	38.93	99.55	(56.17)	(32.73)	(23.70)	(25.94)	(36.06)	(46.42)	(62.58)	(107.88)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LBRX LB Pharmaceuticals Inc	$1.2B	— (loss-making)	—	—	n/m	−579.03% (below 0%: shrinking)	—	0.00%	Compare
BCAX Bicara Therapeutics Inc.	$1.2B	— (loss-making)	—	—	n/m	−72.95% (below 0%: shrinking)	—	0.00%	Compare
DMRA Galecto, Inc.	$1.2B	— (loss-making)	—	—	n/m	−877.51% (below 0%: shrinking)	0.00%	0.00%	Compare
VOR Vor Biopharma Inc.	$1.1B	— (loss-making)	—	—	n/m	−47.59% (below 0%: shrinking)	0.00%	—	Compare
NBTX Nanobiotix S.A. - Sponsored ADR	$1.1B	— (loss-making)	—	−71.69% (below 0%: shrinking)	n/m	−177.26% (below 0%: shrinking)	0.00%	0.00%	Compare
REPL Replimune Group, Inc.	$1.1B	— (loss-making)	—	—	n/m	+5.04% (above 0%: growing)	0.00%	0.00%
IMTX Immatics N.V.	$1.1B	— (loss-making)	— (loss-making)	+97.71% (above 0%: growing)	n/m	−44.41% (below 0%: shrinking)	100.00%	(734.95%)	Compare
JANX Janux Therapeutics, Inc.	$1.1B	— (loss-making)	— (loss-making)	+2,238.72% (above 0%: growing)	n/m	+150.57% (above 0%: growing)	100.00%	(308.66%)	Compare
MNKD MannKind Corporation	$1.0B	— (loss-making)	— (loss-making)	+42.92% (above 0%: growing)	n/m	−399.41% (below 0%: shrinking)	72.99%	(0.32%)	Compare
Median of peers	$1.1B	—	—	+70.31%	—	−125.10%	36.50%	0.00%

All 614 Biotechnology stocks →

Replimune Group, Inc. (REPL) key facts

Replimune Group, Inc. (REPL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, REPL traded at $10.86, a market capitalization of $1.1 billion.
Return on equity was −107.9% and debt-to-equity 1.00.

Source: company filings (standardised) and stockrow calculations.